Psoriatic arthritis is a chronic inflammatory joint disease occurring in up to 30% of patients with psoriasis, encompassing peripheral arthritis, axial involvement, enthesitis, and dactylitis. Biologic therapies, including TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors, have substantially expanded treatment options beyond conventional DMARDs. Treat-to-target strategies and tight monitoring have become central to guideline-recommended care.
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
EULAR 2026 will address the critical need for early, targeted intervention in psoriatic arthritis and axial spondyloarthritis to improve patient outcomes.
Obesity Management Improves Psoriatic Disease Outcomes
Addressing obesity in psoriatic disease patients improves dermatological and musculoskeletal outcomes, highlighting the need for integrated care strategies.
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
EULAR 2026 will address the complex interplay between immune and fibrotic pathways in rheumatic diseases, offering new therapeutic avenues.
EULAR 2026: Psoriatic Disease Spectrum Highlights
EULAR 2026 presentations address the broad clinical manifestations of psoriatic disease, emphasizing early diagnosis and tailored management across its diverse phenotypes.